 |
|
|
| |
Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients:
96 weeks results from maintenance DOLULAM study
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science - Paris, France July 23-26 2017
Jacques REYNES1,2*, Nadia MEFTAH3, Edouard TUAILLON4, Charlohe CHARPENTIER5, Brigihe MONTES4
1. Montpellier University Hospital, Infec7ous Diseases Department, Montpellier, France, 2. University of Montpellier/IRD UMI233/INSERM U1175, Montpellier, France ,
3. COREVIH, Montpellier, France , 4. Montpellier University Hospital, Virology , Montpellier, France, 5. Hôpital Bichat,-Claude Bernard AP-HP, Virology, Paris, France
|
| |
|
|
|
|
|
